Agalsidase beta · Fabrazyme

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Fabry Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
CA
  • FABRAZYME (agalsidase beta) is indicated for: • long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
Product first approved 2004Health Canada
JP
  • Fabry disease
Product first approved 2004ajmc.com
EU
  • Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease
Product first approved 2001EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Fabry Disease
NCT06081062 · ISU Abxis Co., Ltd.
2023-04-14 – 2025-12 · Fabry Disease
What this study did
NCT05843916 · Bio Sidus SA
2022-12-13 – 2025-03-31 · Fabry Disease
What this study did
NCT00074971 · Genzyme, a Sanofi Company
1999-10 – 2004-12 · Fabry Disease
What this study did
Phase 2 (4)
Fabry Disease
NCT01196871 · Amicus Therapeutics
2011-02-02 – 2012-10-09 · Fabry Disease
What this study did
NCT00074958 · Genzyme, a Sanofi Company
2002-10 – 2005-07 · Fabry Disease
What this study did
Phase 4 (10)
Fabry Disease
NCT06019728 · Sanofi
2023-11-10 – 2024-10-25 · Fabry's Disease
What this study did
NCT00230607 · Genzyme, a Sanofi Company
2006-05-28 – 2024-02-09 · Fabry Disease, Alpha Galactosidase A Deficiency
What this study did
NCT05054387 · Genzyme, a Sanofi Company
2021-10-13 – 2023-03-09 · Fabry Disease
What this study did
NCT00312767 · Genzyme, a Sanofi Company
started 2006-04 · Fabry Disease
What this study did
NCT01650779 · Genzyme, a Sanofi Company
2012-04 – 2013-03 · Fabry Disease
What this study did
NCT00140621 · Genzyme, a Sanofi Company
2005-07 – 2012-08 · Fabry Disease
What this study did
NCT00487630 · Assistance Publique - Hôpitaux de Paris
2005-06 – 2009-06 · Fabry Disease
What this study did
NCT00081497 · Genzyme, a Sanofi Company
2004-01 – 2005-09 · Fabry Disease
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Fabry Disease
NCT05280548 · Sanofi
2022-05-03 – 2027-12-06 · Fabry Disease
What this study did
NCT02795676 · Protalix
2016-06 – 2022-07 · Fabry Disease
What this study did
Phase 1 (1)
Fabry Disease
NCT05343715 · Bio Sidus SA
2021-10-23 – 2022-04-17 · Fabry Disease
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Fabry Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Agalsidase Beta (Fabrazyme): this drugApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT00701415: Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks).
NCT00196716: Open-label low-dose-maintenance study, 21 adult Fabry males (matches registry enrollment_count 21): kidney interstitial capillary endothelial GL-3 clearance (primary endpoint) achieved in 100% of patients during the 1.0mg/kg/2wk standard-dose phase and maintained in 90% after switching to the 0.3mg/kg/2wk low-dose maintenance phase.
Migalastat (Galafold)ApprovedSmall moleculeAlpha-galactosidase A (GLA / α-Gal A)Partial signal
NCT00925301: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants missed
Pegunigalsidase AlfaApprovedProtein / enzyme therapeuticAlpha-galactosidase A (GLA / α-Gal A)Weak signal
NCT02795676: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505)
Isaralgagene CivaparvovecPhase 1/2Gene therapy / editingAlpha-galactosidase A (GLA / α-Gal A)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.